KR20180056695A - 신경퇴행성 질병의 치료 - Google Patents

신경퇴행성 질병의 치료 Download PDF

Info

Publication number
KR20180056695A
KR20180056695A KR1020187010855A KR20187010855A KR20180056695A KR 20180056695 A KR20180056695 A KR 20180056695A KR 1020187010855 A KR1020187010855 A KR 1020187010855A KR 20187010855 A KR20187010855 A KR 20187010855A KR 20180056695 A KR20180056695 A KR 20180056695A
Authority
KR
South Korea
Prior art keywords
inhibitor
signaling
egfr
myd88
dependent tlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187010855A
Other languages
English (en)
Korean (ko)
Inventor
피터 리차드슨
리차드 미드
로라 페라이올로
케네스 패트릭 멀배니
Original Assignee
베네볼런트에이아이 바이오 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베네볼런트에이아이 바이오 리미티드 filed Critical 베네볼런트에이아이 바이오 리미티드
Publication of KR20180056695A publication Critical patent/KR20180056695A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187010855A 2015-09-24 2016-09-23 신경퇴행성 질병의 치료 Withdrawn KR20180056695A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1516905.5 2015-09-24
GBGB1516905.5A GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases
PCT/GB2016/052970 WO2017051188A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
KR20180056695A true KR20180056695A (ko) 2018-05-29

Family

ID=54544061

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010855A Withdrawn KR20180056695A (ko) 2015-09-24 2016-09-23 신경퇴행성 질병의 치료

Country Status (13)

Country Link
US (1) US20180263992A1 (enExample)
EP (1) EP3352759A1 (enExample)
JP (1) JP6893917B2 (enExample)
KR (1) KR20180056695A (enExample)
CN (1) CN108025005A (enExample)
AU (1) AU2016329005A1 (enExample)
BR (1) BR112018005855A2 (enExample)
CA (1) CA2999390A1 (enExample)
EA (1) EA201890647A1 (enExample)
GB (1) GB201516905D0 (enExample)
MA (1) MA42930A (enExample)
MX (1) MX2018003619A (enExample)
WO (1) WO2017051188A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077595A1 (en) 2014-11-12 2016-05-19 The General Hospital Corporation Methods for treating neurodegenerative diseases
GB201714307D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714311D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714316D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatement of neurodegenerative diseases
GB201714303D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113694047A (zh) * 2021-08-31 2021-11-26 杭州师范大学 β-石竹烯在制备抗肿瘤药物中的应用
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US257403A (en) * 1882-05-02 Electric lighting apparatus
US62342A (en) * 1867-02-26 Improved tool for the manufacture of paper bags
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2484797A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
JP4328500B2 (ja) * 2002-07-25 2009-09-09 独立行政法人農業・食品産業技術総合研究機構 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
JP2006522124A (ja) * 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
ES2673158T3 (es) * 2004-02-09 2018-06-20 Mitsubishi Tanabe Pharma Corporation Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
RU2405566C9 (ru) * 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
JP2008061505A (ja) * 2006-09-04 2008-03-21 Hisamitsu Pharmaceut Co Inc 筋萎縮性側索硬化症の治療剤のスクリーニング方法
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
EP2490698A4 (en) * 2009-10-22 2013-09-25 Hoffmann La Roche MODULATION OF AXONES DEGENERATION
WO2014018932A2 (en) * 2012-07-27 2014-01-30 Bunt Antonius Martinus Gustave Effluz inhibitor compositions and methods of treatment using the same

Also Published As

Publication number Publication date
MA42930A (fr) 2018-08-01
CA2999390A1 (en) 2017-03-30
GB201516905D0 (en) 2015-11-11
US20180263992A1 (en) 2018-09-20
JP2018534259A (ja) 2018-11-22
EA201890647A1 (ru) 2018-09-28
JP6893917B2 (ja) 2021-06-23
EP3352759A1 (en) 2018-08-01
AU2016329005A1 (en) 2018-04-19
WO2017051188A1 (en) 2017-03-30
MX2018003619A (es) 2018-08-01
BR112018005855A2 (pt) 2018-10-16
CN108025005A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
KR20180056695A (ko) 신경퇴행성 질병의 치료
JP2023062133A (ja) 翼状片を治療するための組成物及び方法
US20100056604A1 (en) Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv
US20180280393A1 (en) Methods and compositions for treatment of metastatic and refractory cancers and tumors
ES2962526T3 (es) Secretagogos PAR-4 para el tratamiento del cáncer
US20180243284A1 (en) Therapeutic agent or treatment method for philadelphia chromosome-positive (ph+) acute lymphocytic leukemia (all) having ikzf1 mutation
KR20170095367A (ko) 조직 석회화의 치료 방법
Dabouz et al. An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration
CN101801386A (zh) 抗血管生成剂和使用方法
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
Skopiński et al. New perspectives of immunomodulation and neuroprotection in glaucoma
JP2013501808A (ja) アポトーシスを促進し、かつ転移を阻害する方法
KR20230074533A (ko) Csf1r 키나아제 억제제 및 이의 용도
WO2019048852A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
CN103391782A (zh) 用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物
US20210069189A1 (en) Treatment of neurodegenerative diseases
KR20220014818A (ko) 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물
US9511068B2 (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
US20230165873A1 (en) Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19
WO2019048851A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
Garcia et al. IL-8 receptor signaling as a novel target for angiogenic retinopathies
WO2019048853A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
Köstek et al. Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient
KR102077807B1 (ko) 피르비늄 및 폴리크레술렌을 포함하는 교모세포종 예방 또는 치료용 약학조성물
WO2022217068A1 (en) Methods of treatment for leukemia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination